MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

MBX Biosciences, Inc. Common Stock

FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

Nuri Clinic offers access to advanced peptide therapy and holistic health services, including live support from medical professionals.

Nuri Clinic

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine disorders. The company aims to create treatments for rare endocrine diseases and endocrine-related cancers.

MBX Biosciences

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed. 

BioCrossroads

New Enterprise Associates

Twilight Venture Partners

Indiana University Philanthropic Venture Fund

OrbiMed

Frazier Healthcare Partners

RA Capital Management

Wellington Management

Norwest Venture Partners

Frazier Life Sciences

Deep Track Capital

Driehaus Capital Management

MBX Biosciences, Inc.

We’re proud to announce the completion of a $63.5 million Series C financing round. Funds will go towards supporting our ongoing Phase 2 clinical study of MBX-2109 in #hypoparathyroidism and accelerating our early-stage pipeline programs for the treatment of #endocrine and #metabolic disorders. Learn more about the news and our commitment to making a meaningful impact in the lives of these patients: https://lnkd.in/eSTR5Jnf

We are proud to share that our Chief Executive Officer and Co-Founder, Kent Hawryluk, and Scientific Co-Founder, Richard DiMarchi, Ph.D., have been named to the 2024 Indiana 250: a list of the state’s most influential and impactful business and community leaders!

This recognition from IBJ Media, Indianapolis Business Journal, and Inside INdiana Business recognizes their outstanding leadership, vision, and contributions to therapeutic innovation to improve patient lives throughout our communities and beyond. Join us in congratulating Kent and Dr. DiMarchi on this prestigious honor! See the full list here: https://bit.ly/3W7c3xE

 #Indiana250

#ICYMI Our Scientific Co-Founder, Richard DiMarchi, Ph.D., was recently awarded the Mani L. Bhaumik 2023 Breakthrough of the Year Award from the AAAS!

Dr. DiMarchi is a world class innovator, inventor and one of the world’s leading peptide chemists who helped lay the foundation for the development of new classes of therapeutic agents that effectively treat #obesity and reduce the risk of #diabetes. 

Thanks to the pioneering work of Dr. DiMarchi, patients have a range of treatment options to help better manage their conditions and improve their quality of life. 

Join us in congratulating Dr. DiMarchi for this well-deserved recognition!  

Missed the ceremony? Watch a replay here: https://lnkd.in/eghP7nCB

The STEM Connection is an amazing non-profit in northern Indianapolis that connects children from diverse backgrounds to STEM educational activities. Last week, MBX Biosciences gathered our growing team from across the country for a Together Week at our home office in Carmel, IN. Together Weeks allow MBXers to connect with each other, the patient community we hope to serve and the local community. We are so happy to have spent time with The STEM Connection, as we value their mission and the work they do. We hope to one day employ STEM professionals whose passions were ignited by the efforts of The STEM Connection.

We’re thrilled to announce the appointment of Salomon (Sam) Azoulay, M.D., as Chief Medical Officer of MBX Biosciences! Dr. Azoulay’s extensive expertise in drug development and operations will be an invaluable asset to our team, where he will oversee MBX’s global clinical development pipeline as we progress our precision peptide candidates for the treatment of endocrine and metabolic disorders.

Learn more about Dr. Azoulay and read the full release here: https://bit.ly/4cEL2ID

As we observe #RareDiseaseDay, MBX is honored to stand with the global community to shine a light on the challenges faced by over 300 million people living with #rarediseases, many of which are serious and rare endocrine disorders. Every day, we strive to advance new treatment options for patients living with these diseases. 

From our office in Carmel, Indiana to our growing lab space in Indianapolis and other remote hybrid/remote locations, here are some of our incredible team members wearing stripes in honor of Rare Disease Day:
 
#showyourstripes

Metric
Company Name	MBX Biosciences, Inc. Common Stock	FiercePharma	Nuri Clinic
Symbol	MBX
MSH ID	COM:MBXBIO	COM:FIERCEPHARMA	COM:NURICLINIC
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Health and Wellness
Country	US	US	US
Stage
Employee Count	36
Website	mbxbio.com	fiercepharma.com	nuriclinic.com
LinkedIn	mbx-biosciences-inc
Founders

Metric
Market Cap	374.48M
Enterprise Value
Monthly Web Traffic		484.53K
Web Traffic Growth		-0.10
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MBXBIO

MBX Biosciences

Last Close

16.51

22/11 21:00

Market Cap

374.48M

Beta: -

Volume Today

126.81K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue